Antibodies
7 September 2023
DotBio announces that its partner Junshi Biosciences has received approval from NMPA to advance JS207 into clinical studies7 September 2023
Corteria Pharmaceuticals Announces a €65M ($71M1) Financing to Advance Transformational Medicines in Cardiovascular Diseases6 September 2023
Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza6 September 2023
Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer6 September 2023
Update on US regulatory review of Ultomiris in NMOSD6 September 2023
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition4 September 2023
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 531 August 2023
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)30 August 2023
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC29 August 2023
AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis29 August 2023
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid TumorsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports